ALOXI Drug Patent Profile

When do Aloxi patents expire, and when can generic versions of Aloxi launch?

Aloxi is a drug marketed by Helsinn Hlthcare and is included in two NDAs.

The generic ingredient in ALOXI is palonosetron hydrochloride. There are twenty-one drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the palonosetron hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aloxi

A generic version of ALOXI was approved as palonosetron hydrochloride by SANDOZ on October 13^th, 2015.

Summary for ALOXI

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	147
Patent Applications:	4,555
Drug Prices:	Drug price information for ALOXI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ALOXI
What excipients (inactive ingredients) are in ALOXI?	ALOXI excipients list
DailyMed Link:	ALOXI at DailyMed

See drug prices for ALOXI

Paragraph IV (Patent) Challenges for ALOXI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ALOXI	Injection	palonosetron hydrochloride	0.05 mg/mL, 1.5 mL and 5 mL vials	021372	3	2011-05-27

US Patents and Regulatory Information for ALOXI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	CAPSULE;ORAL	022233-001	Aug 22, 2008		DISCN	Yes	No
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	INJECTABLE;INTRAVENOUS	021372-002	Feb 29, 2008		DISCN	Yes	No
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	INJECTABLE;INTRAVENOUS	021372-001	Jul 25, 2003		DISCN	Yes	No

Expired US Patents for ALOXI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	CAPSULE;ORAL	022233-001	Aug 22, 2008	5,202,333
Helsinn Hlthcare	ALOXI	palonosetron hydrochloride	INJECTABLE;INTRAVENOUS	021372-002	Feb 29, 2008	9,125,905

International Patents for ALOXI

See the table below for patents covering ALOXI around the world.

Country	Patent Number	Title	Estimated Expiration
Luxembourg	91162
Tunisia	SN05180	LIQUID PHARMACEUTICAL FORMULATIONS OF PALONOSETRON
Poland	166277
Australia	6696390
China	102813621	Liquid pharmaceutical formulations of palonosetron
Norway	2005023
Netherlands	300194

Supplementary Protection Certificates for ALOXI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0430190	300194	Netherlands		300194, 20101127, EXPIRES: 20151126
1035115	92745	Luxembourg		PRODUCT NAME: NETUPITANT/PALONOSETRON ET LEURS DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (AKYNZEO); FIRST REGISTRATION: 20150527
0430190	91162	Luxembourg		91162, EXPIRES: 20151127
2785706	LUC00158	Luxembourg		PRODUCT NAME: AKYNZEO - FOSNETUPITANT/PALONOSETRON; AUTHORISATION NUMBER AND DATE: EU/1/15/1001 20200318
2785706	122020000046	Germany		PRODUCT NAME: FOSNETUPITANT MIT PALONOSETRON; REGISTRATION NO/DATE: C(2020)1804(FINAL) 20200316
0430190	SPC/GB05/032	United Kingdom		PRODUCT NAME: PALONOSETRON OR AN ISOMER, MIXTURE OF ISOMERS, N-OXIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/306/001 20050322
0430190	CA 2005 00023	Denmark

Aloxi (palonosetron): Market dynamics and financial trajectory

Last updated: April 25, 2026

What is Aloxi and where does it sit in the oncology antiemetic stack?

Aloxi is the brand name for palonosetron, a 5-HT3 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV). In oncology supportive care, the market has shifted over time toward multi-day, multi-mechanism regimens that combine a 5-HT3 antagonist with agents such as NK1 receptor antagonists (e.g., aprepitant/fosaprepitant/rolapitant) and corticosteroids.

For investment and R&D decisions, Aloxi’s commercial relevance is tied to three durable demand drivers:

1. CINV prevention protocols that use a long-acting 5-HT3 antagonist to cover the delayed phase.
2. Formulation and dosing convenience that supports real-world regimen adherence.
3. Competitive positioning versus other 5-HT3 antagonists with shorter durations and different dosing profiles.

How does competition shape pricing power and share?

The competitive set for Aloxi is anchored in other 5-HT3 antagonists, with the key market dynamic being clinical differentiation versus generics.

Competitive implications

• Generic erosion risk is a constant across mature CINV agents as patents expire and manufacturing scales.
• Differentiation-by-duration has historically supported premium pricing for palonosetron relative to shorter-acting 5-HT3 antagonists, especially when protocols prioritize delayed-phase control.
• Formulary access is the gatekeeper. Even when clinical differentiation exists, payers and hospital systems typically drive utilization toward the formulary-preferred agent and regimen template.

Practical market outcomes seen in hospital antiemetic portfolios

• In many settings, formularies cluster around:
  • a preferred long-acting 5-HT3 antagonist (where palonosetron is advantaged),
  • an NK1 backbone for higher emetogenic chemotherapy, and
  • steroids and rescue antiemetics.
• Where formulary committees favor cost-minimized 5-HT3 options, Aloxi faces tighter volume and pricing even with comparable efficacy endpoints.

What demand signals matter for Aloxi’s trajectory?

Aloxi’s demand correlates with chemotherapy administration trends and supportive-care protocol intensity.

Demand drivers

• Oncology drug pipeline volume: more regimen approvals can lift antiemetic use, but supportive-care intensity varies by regimen emetogenicity.
• Protocol adherence: hospitals stick to guideline-driven regimens for prophylaxis; long-acting agents gain if they reduce dosing complexity.
• Patient mix: higher use in regimens with significant delayed nausea propensity increases the value proposition of long-acting 5-HT3 coverage.

Demand headwinds

• Generic substitution in 5-HT3 class
• Protocol standardization toward cost-optimized agent selection
• Payer utilization controls: prior authorization and step edits can reduce uptake where therapeutically equivalent alternatives exist.

How has Aloxi’s financial trajectory evolved in practice?

Aloxi’s financial trajectory has been shaped by the interplay of:

• patent-protected premium years,
• loss of exclusivity and generic entry risk, and
• formulary and tender pressures that compress gross margin over time.

Key commercial trajectory markers (qualitative, protocol-driven)

1. Early lifecycle: strong uptake driven by differentiation as a long-acting 5-HT3 antagonist and clinician adoption for delayed-phase CINV.
2. Mid lifecycle: sustained use in oncology centers, with gradual normalization as competition deepens across 5-HT3 alternatives.
3. Later lifecycle: margin pressure and utilization shifts where generics broaden and hospital procurement targets cost per treated patient.

What does the market structure imply for forward revenue stability?

Aloxi’s forward trajectory is typically more stable than single-cycle supportive care products because:

• CINV prophylaxis is a recurring supportive need tied to ongoing chemotherapy administrations.
• Hospital formularies and order sets can lock in antiemetic regimen defaults.
• However, stability depends on whether palonosetron’s differentiation continues to outweigh payer and procurement cost pressure.

Revenue sensitivity framework

• Volume risk increases when formularies displace long-acting 5-HT3 use with lower-cost equivalents.
• Price/mix risk increases when tender pricing and conversion to generics compress net pricing.
• Offset potential comes from sustained oncology treatment volumes and continued protocol preference for long-acting 5-HT3 coverage in delayed phase regimens.

How do regulatory and lifecycle events typically influence Aloxi economics?

Lifecycle economics in antiemetics usually hinge on exclusivity windows and subsequent generic availability. For Aloxi, the market has progressed through stages common to mature branded injectables:

• exclusivity-supported pricing,
• adoption into standard regimen templates, then
• commercial compression when alternatives become available at lower cost.

Where is Aloxi exposed to policy and payer shifts?

Supportive care products face increasing payer scrutiny under:

• bundled chemotherapy episode cost management,
• oncology pharmacy benefit controls,
• hospital procurement consolidation,
• and formulary governance emphasizing cost-effectiveness.

For Aloxi, exposure is highest where:

• a payer or group purchasing organization negotiates competitive tender pricing and drives standardization to lower-cost class members.

What is the likely financial trajectory range under current dynamics?

Given the typical maturation path of 5-HT3 antagonists, Aloxi’s financial outlook tends to follow a pattern:

• declining branded net sales growth after peak adoption and before or during generic competition windows,
• stabilization at lower net pricing if palonosetron retains formulary position for delayed-phase protocol advantages,
• further declines if long-acting preference is displaced by cost-minimized class substitutes.

Is there evidence Aloxi is still outperforming within 5-HT3?

The core question in the market is whether palonosetron remains a formulary winner for delayed-phase CINV.

Factors supporting continued relative performance:

• dosing profile supports protocol convenience,
• clinicians value delayed-phase coverage,
• real-world order sets in oncology centers can preserve utilization.

Factors undermining relative outperformance:

• generic price competition,
• formulary switching incentives under cost-containment.

Key Takeaways

• Aloxi (palonosetron) sits in the 5-HT3 antiemetic backbone for CINV prevention, with market value tied to delayed-phase coverage and protocol-driven adoption.
• Competition and generics in the 5-HT3 class drive pricing and share pressure as formularies and procurement committees target cost per treated patient.
• Financial trajectory is shaped by lifecycle maturity: exclusivity-supported premium years transition into margin compression and utilization shifts when lower-cost alternatives broaden.
• Forward revenue stability depends on formulary retention of long-acting 5-HT3 use within multi-agent prophylaxis regimens and on oncology treatment volumes.

FAQs

1. What is Aloxi used for?
   Aloxi (palonosetron) is used to prevent chemotherapy-induced nausea and vomiting and postoperative nausea and vomiting.

2. What differentiates Aloxi versus other 5-HT3 antagonists?
   Palonosetron’s clinical positioning in delayed-phase CINV protocols and its long-acting profile relative to many shorter-acting 5-HT3 comparators.

3. What are the biggest financial risks for Aloxi?
   Generic substitution and formulary switching driven by cost-containment in hospital oncology supportive care.

4. What supports demand for Aloxi?
   Ongoing chemotherapy administrations and protocol adherence to CINV prophylaxis regimens that include a long-acting 5-HT3 antagonist.

5. What most determines Aloxi’s market share trajectory?
   Hospital formulary decisions, group purchasing negotiations, and regimen order-set defaults.

---

References

[1] FDA. “Aloxi (palonosetron) prescribing information.” U.S. Food and Drug Administration.